This Page Is Inserted by IFW Operations and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

As rescanning documents will not correct images, please do not report the images to the Image Problem Mailbox.

Amendments to the Specification

At page 9 of the application below line 21, please reeplace the image shown with the 1. following image (one "R₁" group has been corrected to read "R₂"):

2. At column 6 line 42, the word "a" following the word "preferably" should be deleted.

As before, R₁ and R₂ are preferably a-long chain fatty acids between 12 and 24 carbons in length. The variable "n" is preferably an integer between 11 and 46. A number of specific derivatives of the a generic structural configuration of a subset of the group of related lipid molecules of the invention seen in FIG 2 have been synthesized and tested for their ability to inhibit phospholipase A2 and cyclooxygenase-2. Table 2 below lists and describes a number of such derivatives.

Amendments to the Claims

This listing of claims will replace all prior version, and listings, of claims in the application:

1) A lipid compound represented by the formula

Serial Number: 10/680,042